Related Experiment Video

Updated: May 20, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer

David E Schteingart1, Joseph E Sinsheimer, Ricardo S Benitez

  • 1Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan. Rm 5570, MSRB 2. 1150 West Medical Center Dr, Ann Arbor, MI 48109, USA. dschtein@umich.edu

Anticancer Research
|July 4, 2012
PubMed
Abstract

Insights

New mitotane analogs show improved adrenal cancer treatment potential. Dihalogenated methine carbon is key for activity, with o,p'-DDBr(2) demonstrating enhanced efficacy at lower concentrations.

Area of Science:

  • Endocrinology
  • Oncology
  • Medicinal Chemistry

Background:

  • Mitotane is a standard treatment for adrenal cancer, but response rates are low (30%).
  • Understanding mitotane's structural requirements is crucial for developing more effective therapies.
  • Existing treatments face challenges with efficacy and patient response.

Purpose of the Study:

  • To identify structural features essential for mitotane's adrenalytic activity.
  • To synthesize and evaluate novel mitotane analogs with potentially enhanced anti-cancer effects.
  • To improve therapeutic outcomes for patients with adrenal cancer.

Main Methods:

  • Synthesis of nine analogs based on o,p'-DDD (mitotane).
  • In vitro testing using NCI-H295 human adrenal cancer cells to assess proliferation and cortisol production.
  • In vivo testing in dogs to evaluate cortisol suppression and adrenal inflammatory changes.

Main Results:

  • Mitotane, o,p '-DDClBr, and o,p '-DDBr(2) exhibited activity.
  • o,p '-DDBr(2) showed significantly higher activity than o,p '-DDD at a lower concentration (20 μM vs. 50 μM).
  • Structural modifications to the aromatic portion of mitotane resulted in loss of activity.

Conclusions:

  • A dihalogenated methine carbon is essential for adrenalytic activity.
  • o,p '-DDBr(2) displays superior potency and may offer a more effective treatment option for adrenal cancer.
  • Further investigation of o,p '-DDBr(2) is warranted for clinical application.

More Related Videos

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...